MedPath

Comparison efficacy of olanzapine when added to nutritional weight gain improvement in advanced cancer patients receiving chemotherapy: A randomized placebo-controlled trial

Phase 2
Conditions
Advanced stage cancer who will receive chemotherapy treatment
Olanzapine, weight gain, quality of life, anorexia,
Registration Number
TCTR20240524004
Lead Sponsor
Rajavithi hospital, Thailand
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending (Not yet recruiting)
Sex
All
Target Recruitment
60
Inclusion Criteria

1. Advanced stage cancer who will receive chemotherapy treatment
2. Age>= 18 years
3. ECOG 0-2
4. Life expectancy > 3 months
5. Sign inform consent

Exclusion Criteria

1. Concurrent chemoradiation
2. Receiving other antidepressants or antipsychosis
3. NG, NJ tube insertion
4. Corticosteroids treatment more than 1 months
5. Megestrol acetate treatment
6. Pregnancy or breastfeeding
7. Olanzapine allergy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
weight gain 12 weeks weight change measurement kilogram record by SaintMed super smart society 5.0 machine by patient self-standing then recording by nurse aid
Secondary Outcome Measures
NameTimeMethod
Quality of life 12 weeks EORTC QLQ-C30,Anorexia 12 weeks VAS scale/FAACT A/CS
© Copyright 2025. All Rights Reserved by MedPath